Jacobio Pharmaceuticals Group (HKG:1167) said the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approved its Investigational New Drug (IND) application of its cancer drug JAB-23E73, according to a Thursday filing with the Hong Kong bourse.
The drug's IND application was previously approved by US FDA, and also plans to initiate the Phase I/IIA clinical trial in advanced solid tumor patients in China and the US.
The pharmaceutical stocks were up by almost 3% in recent trading.
Price (HKD): $1.77, Change: $+0.030, Percent Change: +1.72%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.